ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application for Anktiva in combination with Bacillus Calmette-Guerin for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The EMA covers 27 countries in the European Union, as well as Iceland, Norway and Liechtenstein.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX: